The purpose of this research is to see if adjusting the dose of 5-fluorouracil based on its concentration in your blood will improve the treatment of your metastatic colon cancer.

Start Date15 Dec 2025

Sponsor / Collaborator

Inova Health Care Services

NCT06939751

/ Not yet recruitingNot ApplicableIIT

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels (Optimal)

This study aims to develop and refine a miR biomarker panel that can be used to phenotype net immune state after heart transplantation.

Start Date03 Jun 2025

Sponsor / Collaborator

Inova Health Care Services

[+1]

NCT06564207

/ Not yet recruitingPhase 2IIT

Randomized, Double-Blinded, Placebo-Controlled Phase 2 Study for the Long Term Evaluation of Fostamatinib for the Treatment of Adult Patients With Acute Respiratory Distress Syndrome (ARDS)

This study is designed to evaluate the safety and efficacy of fostamatinib in hospitalized adult participants with acute respiratory distress syndrome (ARDS).

Start Date01 May 2025

Sponsor / Collaborator

Inova Health Care Services

[+2]

100 Clinical Results associated with Inova Health Care Services

0 Patents (Medical) associated with Inova Health Care Services

2,467

Literatures (Medical) associated with Inova Health Care Services

01 Dec 2025·Lung

Performance of the FORD Versus Other Available Models for the Noninvasive Prediction of Pulmonary Hypertension in Patients with Interstitial Lung Disease

Article

Author: Chandel, Abhimanyu ; Tomic, Rade ; Shawabkeh, Malek ; Kim, Min Jee ; Nathan, Steven D ; Arunachalam, Ambalavanan ; King, Christopher S ; Kim, Ho Cheol

PURPOSEPulmonary hypertension (PH) is associated with morbidity and mortality in patients with interstitial lung disease (ILD). Several prediction models have been proposed to predict PH in ILD patients. We sought to discern how previously described prediction models perform in predicting PH in patients with ILD.METHODSPatients with ILD who completed a baseline right heart catheterization, from Inova Fairfax Hospital, Northwestern Memorial Hospital, and Asan Medical Center in Korea were enrolled. The performance of various prediction models (FORD model, the FORD calculator, the PH-ILD Detection tool, and the mean pulmonary artery pressure prediction model) were assessed using receiver operating characteristic (ROC) curves and area under the receiver operating characteristic curve (AUROC). There were four definitions of pulmonary hypertension against which the models were evaluated.RESULTSThere were a total of 192 patients with ILD, of whom 32.8% (n = 63/192) met the modified 5th world symposium on PH definition of precapillary PH. Among the models assessed, the FORD calculator had an AUROC (0.733) that was marginally highest. Subgroup analysis revealed that the FORD index had the highest AUROC (0.817) in patients with idiopathic pulmonary fibrosis, while the FORD calculator had the highest AUROC (0.751) in patients with non-IPF ILD.CONCLUSIONThe FORD model can be used to predict group 3 PH in both IPF patients and non-IPF ILD patients. It could serve as a tool for ILD patient selection for right heart catheterization as well as an enrichment tool for clinical trials targeting the pulmonary vasculature.

01 Dec 2025·Clinical Proteomics

Histology-resolved proteomics reveals distinct tumor and stromal profiles in low- and high-grade prostate cancer

Article

Author: Barakat, Waleed ; Abulez, Tamara ; Pienta, Kenneth J ; Ogata, Jonathan ; Hunt, Allison L ; Hood, Brian L ; Makohon-Moore, Sasha C ; Lotan, Tamara L ; Trump, Donald L ; Conrads, Thomas P ; Conrads, Kelly A ; Wilson, Katlin N ; Bateman, Nicholas W ; Mani, Haresh

BACKGROUNDProstate cancer is one of the most frequently diagnosed cancers in men. Prostate tumor staging and disease aggressiveness are evaluated based on the Gleason scoring system, which is further used to direct clinical intervention. The Gleason scoring system provides an estimate of tumor aggressiveness through quantitation of the serum level of prostate specific antigen (PSA) and histologic assessment of Grade Group, determined by the Gleason Grade of the tumor specimen.METHODSTo improve our understanding of the proteomic characteristics differentiating low- versus high-grade prostate cancer tumors, we performed a deep proteomic characterization of laser microdissected epithelial and stromal subpopulations from surgically resected tissue specimens from patients with Gleason 6 (n = 23 specimens from n = 15 patients) and Gleason 9 (n = 15 specimens from n = 15 patients) prostate cancer via quantitative high-resolution liquid chromatography-tandem mass spectrometry analysis.RESULTSIn total, 789 and 295 grade-specific significantly altered proteins were quantified in the tumor epithelium and tumor-involved stroma, respectively. Benign epithelial and stromal populations were not inherently different between Gleason 6 versus Gleason 9 specimens. Notably, 598 proteins were exclusively significantly altered between Gleason 9 (but not Gleason 6) tumor-involved stroma and benign stroma, including several proteins involved in cholesterol biosynthesis and nucleotide metabolism.CONCLUSIONSProteomic alterations between Gleason 6 versus Gleason 9 were exclusive to the disease microenvironment, observed in both the tumor epithelium and tumor-involved stroma. Further, the molecular alterations measured in the tumor-involved stroma from Gleason 9 cases relative to the benign stroma have unique significance in disease aggressiveness, development, and/or progression. Our data provide supportive evidence of a need for further investigations into targeting stromal reservoirs of cholesterol and/or deoxynucleoside triphosphates in PCa tumors and further highlight the necessity for independent examination of the TME epithelial and stromal compartments.

21 Apr 2025·Cancer Research

Abstract 3327: Obesity-mediated extracellular vesicle secretion: A potential target for preventing endometrial hyperplasia and cancer initiation

Author: Velasquez, Jessica ; Maxwell, George Larry ; Sakaue, Takahiko ; Cohn, David E. ; O'Malley, David M. ; Cosgrove, Casey ; Yadagiri, Ganesh ; Karuppaiyah, Selvendiran ; Priya Doraiyappan, Kalpana Deepa ; Sundaram, Shyam ; Chakrapani, Lakshmi Narasimhan

AbstractIntroduction:Endometrial cancer (EC) is the most common gynecologic malignancy in the U.S., with obesity contributing to 57% of cases. This study investigates the molecular mechanisms linking obesity to EC, focusing on extracellular vesicle (EV) secretion and oncogenic protein regulation in adipose and uterine tissues. Understanding these pathways could lead to innovative preventive and therapeutic strategies for obesity-related EC.Methods:Endometrial hyperplasia and cancer were induced in immunocompetent mice using high-fat diets (HFD; 45% or 60% kcal from fat) for 25 weeks. Molecular profiling was performed using LC-MS/MS, while EV quantification and size analysis were conducted via nanoparticle tracking analysis (NTA) and transmission electron microscopy (TEM), respectively. The expression of TMEM205, STAT5, FAS, and PIAS3 was assessed using immunohistochemistry (IHC), ELISA, and RT-PCR in patient and HFD-treated mouse adipose and uterine tissues.Results:EV secretion and the regulation of oncogenic proteins were significantly elevated in adipose and uterine tissues from obese EC patients compared to non-obese controls. In mice fed a 45% or 60% kcal HFD for 25 weeks, we observed increased body weight, abdominal adipose tissue, uterine horn enlargement, and heightened inflammation, correlating with endometrial hyperplasia and cancer initiation. This was associated with increased EV secretion, upregulated TMEM205, FAS, and STAT5 expression, and downregulation of the tumor suppressor PIAS3. Furthermore, HFD-induced EV secretion carrying oncogenic proteins were linked to elevated serum glucose, lipid and Free fatty acid levels. A small-molecule inhibitor, DAP-5, selectively targeting EV secretion, significantly reduced body weight and adipose tissue accumulation in HFD-treated mice. DAP-5 treatment also restored normal uterine morphology and reduced the expression of EV-related oncogenic proteins.Conclusion:This study highlights obesity-mediated EV secretion as a key contributor to the pathogenesis of EC and identifies it as a potential target for prevention. Preclinical findings support further investigation into EV-targeted therapies, including initiating first-in-human trials to prevent obesity-driven EC.Citation Format:Lakshmi Narasimhan Chakrapani, Kalpana Deepa Priya Doraiyappan, Ganesh Yadagiri, Jessica Velasquez, Shyam Sundaram, Takahiko Sakaue, Casey Cosgrove, George Larry Maxwell, David M. O'Malley, David E. Cohn, Selvendiran Karuppaiyah. Obesity-mediated extracellular vesicle secretion: A potential target for preventing endometrial hyperplasia and cancer initiation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 3327.

100 Deals associated with Inova Health Care Services

100 Translational Medicine associated with Inova Health Care Services

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Inova Health Care Services

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 09 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing